Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase II for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). According to GlobalData, Phase II drugs for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Povetacicept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Povetacicept overview

Povetacicept is under development for the treatment of myasthenia gravis, systemic lupus erythematosus, membranous glomerulonephritis, Sjogren's syndrome, proteinuria in IgA nephropathy (Berger's Disease), lupus nephritis, immune thrombocytopenia, acquired (autoimmune) hemolytic anemia, cold agglutinin disease, unspecified antibody-related neurological diseases and autoimmune encephalitis (post-infectious). It is administered through intravenous and subcutaneous route. The drug candidate is an engineered B-cell modulator. It acts by targeting BAFF and APRIL. 

It was also under development for pemphigus foliaceus, pemphigus vulgaris and bullous pemphigoid.

Alpine Immune Sciences overview

Alpine Immune Sciences (Alpine), formerly Nivalis Therapeutics Inc, is a pharmaceutical company. The company focuses on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. The company also provides ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer. It offers a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Alpine is headquartered in Seattle, Washington, the US.

For a complete picture of Povetacicept’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.